Bayer Schering Pharma's new drug rivaroxaban, an oral therapy for deep vein thrombosis (DVT), has demonstrated its effectiveness in a phase III trial.
The treatment, which is being jointly developed by Bayer HealthCare and Johnson and Johnson, was involved in a study known as Einstein-DVT, in which it was compared to a combination of enoxaparin and a vitamin K antagonist.
It was found that the Bayer drug provided non-inferior performance in terms of cumulative incidence of symptomatic recurrent venous thromboembolism, while also providing an encouraging safety profile.
This means that the drug was able to meet its primary endpoint in the trial when compared to a treatment that represents the current standard of care.
Kemal Malik, member of the executive committee and chief medical officer of Bayer HealthCare, said: "The results of this study confirm that the novel, convenient single-drug treatment approach with rivaroxaban could replace the current standard therapy in the treatment of patients suffering from DVT."
Earlier this week, the company published its financial report for the second quarter of 2010, highlighting a 4.3 per cent year-on-year increase in pharmaceutical sales.See all the latest jobs in Pharmaceutical